Cipla Ltd.

CIPLA

₹1640.7

-0.66% (-10.9)

Market Cap

₹1,33,402 Cr.

P/E

31.00

About

Cipla Limited, a global pharmaceutical company established in 1935, is dedicated to providing affordable medicines to those in need. The company manufactures, develops, and markets a wide range of bra… Read more

Cipla Limited, a global pharmaceutical company established in 1935, is dedicated to providing … Read more

Low

1132

52W Range

High

1683

Quick View

CHART MODE

Price

CHART MODE

EV/EBITDA

Price to Sales

Price to Book

CHART MODE

Capex

CHART MODE

Debt

Company Timeline

Subscribe now for more updates

Custom financial statement

Edit rows

Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

1.36 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

7.76 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.96 %

(as of Nov 21)

Historic

Anti-Malarial - Market Share

5.93 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.79 %

(as of Nov 21)

Historic

Blood Related - Market Share

4.48 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

2.19 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.55 %

(as of Nov 21)

Historic

Endocrinology - Market Share

2.37 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

1.85 %

(as of Nov 21)

Historic

Gynecology - Market Share

2.97 %

(as of Nov 21)

Historic

Neurological - Market Share

8.92 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

1.94 %

(as of Nov 21)

Historic

Pain - Market Share

5.30 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

23.76 %

(as of Nov 21)

Historic

Respiratory - Market Share

4.31 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.07 %

(as of Oct 19)

Historic

Stomatological - Market Share

18.51 %

(as of Nov 21)

Historic

Urology - Market Share

0.06 %

(as of Jul 22)

Historic

Vaccines - Market Share

0.62 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up - Global API

Location Wise Break-Up

Therapeutic Area Break-Up - Global API

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

US DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Bronco cough syrup

Coryx

Suppliers

Bharat Dynamics Ltd.
Laurus Labs Ltd.
Atul Ltd.
Aarti Industries Ltd.
Ion Exchange (India) Ltd.
Shakti Pumps (India) Ltd.
EPL Ltd.
Borosil Renewables Ltd.
GMM Pfaudler Ltd.
Aarti Drugs Ltd.
Venus Pipes & Tubes Ltd.
TCI Express Ltd.
Cigniti Technologies Ltd.
Marine Electricals (India) Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
Vidhi Specialty Food Ingredients Ltd.
Gulshan Polyols Ltd.
Allcargo Gati Ltd.
Control Print Ltd.
Empire Industries Ltd.
Hitech Corporation Ltd.
Take Solutions Ltd.
A2Z Infra Engineering Ltd.
Mitsu Chem Plast Ltd.
Arshiya Ltd.
Vivimed Labs Ltd.

Showing 5 of 26

FAQs on Cipla Ltd. Business

What does Cipla do?

Cipla Limited is a global pharmaceutical company founded in 1935, dedicated to providing affordable medicines worldwide. It offers a broad portfolio of branded and generic formulations and APIs across multiple therapeutic segments.

Who are the competitors of Cipla?

Cipla major competitors are Torrent Pharma, Zydus Lifesciences, Dr. Reddy's Lab, Lupin, Mankind Pharma, Aurobindo Pharma, Alkem Laboratories.
Market Cap of Cipla is ₹1,34,028 Crs.
While the median market cap of its peers are ₹1,02,734 Crs.

Is Cipla financially stable compared to its competitors?

Cipla seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Sep			Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec